On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
WednesdayNov 03, 2021 12:38 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio

Lexaria recently announced the commencement of EPIL-A21-1, an animal study to evaluate whether DehydraTECH-CBD has similar or superior efficacy in reducing or inhibiting seizure activity compared to FDA-approved seizure drug, Epidiolex The study will also compare DehydraTECH-CBD to generic CBD EPIL-A21-1 has entered early-stage preparatory work, with results expected in Q3 2022 Lexaria received new patent awards in Mexico and Japan, strengthening its IP portfolio to 23 granted patents Lexaria Bioscience (NASDAQ: LEXX), the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology, recently announced it had commenced an important new animal study, EPIL-A21-1 (https://cnw.fm/iMVe3). EPIL-A21-1, which will be…

Continue Reading

WednesdayNov 03, 2021 4:20 am

420 with CNW — Senate Committee Asks State Department to Account for Funds Spent on Drug War

A recent report filed by top senators has asked the State Department to explain how the billions in funding that was injected into various counter-narcotics programs across Latin America were used, as these programs haven’t yielded results. The report also calls out the federal government over the failed war on drugs. The report is part of the bill to finance the federal government that Chairman Patrick Leahy of the Senate Appropriations Committee introduced a couple of days ago. The panel stated that the incidence of corruption and violence related to drug trafficking in Latin America has increased steadily since the…

Continue Reading

TuesdayNov 02, 2021 4:20 pm

420 with CNW — Lung Cancer Case Report Triggers Calls for Additional Research on Cannabidiol

Although cannabidiol (“CBD”) has grown extremely popular over the past couple of years thanks to anecdotal user claims of medical efficacy, most scientists have been reluctant to say anything conclusive until they carry out more in-depth research. Users have claimed that CBD can be effective against pain, anxiety, depression, and insomnia; in limited circles, some even claim that the hemp extract can kill cancer cells. But as the research on CBD’s potential benefits and risks is limited and in its infancy, experts have cautioned against using CBD as an alternative to prescribed medication, especially when life-threatening conditions like cancer are…

Continue Reading

TuesdayNov 02, 2021 12:59 pm

Cannabis Strategic Ventures Inc. (NUGS) Is ‘One to Watch’

Cannabis Strategic Ventures’ 2020 revenue jumped 517% year-over-year to $14.6 million 2020 revenues from cannabis sales were $14.1 million, up 975% compared to fiscal 2019 The company’s gross profit spiked 483% year-over-year, reaching $2.78 million in 2020, while gross margins held steady at about 20 percent Cannabis Strategic Ventures will launch its first Los Angeles dispensary in Q4 2021 The company will open an indoor cultivation facility with capacity to produce up to 15,000 pounds of premium cannabis flower annually Cannabis Strategic Ventures (OTC: NUGS) is an emerging leader in the U.S. cannabis marketplace as a publicly traded cannabis cultivator.…

Continue Reading

TuesdayNov 02, 2021 4:20 am

420 with CNW — New York Cannabis Regulators to Allow Patients to Grow Medical Cannabis

The Cannabis Control Board in the state of New York has voted to allow medical marijuana patients to grow marijuana for personal use. The cannabis regulators plan to file the proposed regulations, which will permit patients who meet the criteria to grow up to six plants, either outdoors or indoors, for their own therapeutic use. Once the regulations have been published, the public will be afforded a 60-day comment period. After this, the board will review these comments and make any amendments they deem necessary, after which the regulations will be filed officially in order to take effect. The chair…

Continue Reading

MondayNov 01, 2021 4:20 pm

420 with CNW — NIDA Tells Congress Drug Scheduling Is Hindering Cannabis Research

Marijuana’s federal classification as a Schedule I controlled substance has consistently been a thorn in the plant’s side, especially as more states have chosen to legalize it in various capacities. With the drug more accessible to the public than it has ever been thanks to state cannabis reform, a growing number of people have been using cannabis either medically or recreationally. As cannabis becomes even more popular among the masses, most experts agree that the hype around it and its purported medical abilities has far outpaced the science and that more research on marijuana’s potential benefits and risks is needed.…

Continue Reading

MondayNov 01, 2021 1:49 pm

Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production

Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly listed Ginkgo Bioworks Holdings Inc., in what is the largest-ever biotechnology go-public transaction Ginkgo Bioworks is known for its work in the commercial-scale production of a rare cannabinoid, CBG, for use in a multitude of industrial needs InMed uses multiple manufacturing approaches to synthetically produce rare cannabinoids, including CBC which is currently sold through its subsidiary BayMedica The success of the Ginkgo IPO suggests the marketplace value associated with the production of rare cannabinoids  Special purpose acquisition company (“SPAC”) Soaring Eagle Acquisition Corp. (NASDAQ: SRNGU,…

Continue Reading

MondayNov 01, 2021 11:49 am

The Cannabis World Congress & Business Exposition (‘CWCBExpo’) Establishes Itself as a Key Forum for Establishing a Foothold Within New York’s Burgeoning Cannabis Sector

New York’s recreational marijuana market is poised to begin with a bang — and the Cannabis World Congress & Business Exposition (“CWCBExpo”), which is being held at New York City’s Javits Convention Center, Hall 3A between 4-6 November 2021, is the ideal forum for education, business building and networking on this multifaceted industry. As of Sept. 21, 2021, adult New Yorkers are now able to possess up to three ounces of cannabis for recreational use or up to 24 grams of concentrated cannabis, such as oils derived from a cannabis plant (https://cnw.fm/1gF1p). With the state’s cannabis industry expected to begin…

Continue Reading

MondayNov 01, 2021 4:20 am

420 with CNW — Real Estate Survey Shows Proximity to Marijuana Firms Is Attractive

In just a few short years, marijuana reform legislation has had a major impact. The nascent industry has created thousands of new jobs, generated billions of dollars in revenue and filled state coffers with millions in tax money. With every passing day, attitudes on the controversial plant are evolving and changing, undoing the damage done by decades of federal prohibition little by little. That was very evident when most states with legal cannabis markets declared it essential and went to great lengths to ensure people still had access to their medical marijuana, especially immunocompromised individuals who had no choice but…

Continue Reading

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722